<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002339</url>
  </required_header>
  <id_info>
    <org_study_id>FundacionRC</org_study_id>
    <nct_id>NCT01002339</nct_id>
  </id_info>
  <brief_title>Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation</brief_title>
  <acronym>01-DMPT</acronym>
  <official_title>Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Torres Ramírez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New onset diabetes after renal transplantation (NODAT) is a common and severe complication
      negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the
      basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection
      and graft function. However, Tacrolimus increases 2 times the risk of NODAT as compared to
      CsA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New onset diabetes after renal transplantation (NODAT) is a common and severe complication
      negatively influencing graft and patient survival. CsA and Tacrolimus are the basis of modern
      immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection and graft
      function. However, increases 2 times the risk of NODAT as compared to CsA. Objectives: a) To
      compare the incidence of NODAT and glucose intolerance with 3 different regimes: Tacrolimus
      with rapid steroid withdrawal; Tacrolimus with steroids minimization; and CsA with steroid
      minimization; b) To compare acute rejection rate, renal function and graft and patient
      survival between different regimes; and c) to investigate the influence of different regimes
      on subclinical atheromatosis. A total of 210 patients will be randomized. The primary
      efficacy variable will be NODAT or glucose intolerance at 1 year; secondary efficacy
      variables will be acute rejection, renal function, and changes of carotid intima-media
      thickness over time.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated: higher rate of acute rejection in the Cyclosporin A group
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure &quot;New Onset Diabetes After Renal Transplantation&quot; (NODAT)</measure>
    <time_frame>1 year</time_frame>
    <description>American Diabetes Association criteria (ADA) including an oral glucose tolerance test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients Treated With Insulin or Oral Antidiabetic Drugs</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome Measure (Glucose Intolerance)</measure>
    <time_frame>1 year</time_frame>
    <description>Glycemia &gt;=140 and &lt;200 mg/dl, 2 hours after a standard oral glucose tolerance test. Measured values: glucose intolerance at 1 year defined by ADA criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>1 year</time_frame>
    <description>Biopsy proven acute rejection. Measured variable: Rate of Biopsy proven acute rejection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>1 year</time_frame>
    <description>Estimated Glomerular Filtration Rate (ml/min/1.73 m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>1 year</time_frame>
    <description>Systolic pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>1 year</time_frame>
    <description>Diastolic pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Antihypertensive Drugs Patients Reported Taking.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic Profile (Triglycerides)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic Profile (Cholesterol)</measure>
    <time_frame>1 year</time_frame>
    <description>Lipidic Profile (total cholesterol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic Profile (HDL-c)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidic Profile (LDL-c)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Using Statins</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Carotid Intima-media Thickness Over Time</measure>
    <time_frame>1 year</time_frame>
    <description>absolute difference between carotid intima-media thickness at study end versus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Using Acetylsalicylic Acid (ASA)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Diabetes Mellitus, Adult-Onset</condition>
  <arm_group>
    <arm_group_label>Tacrolimus with rapid steroid withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus with steroids minimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CsA with steroid minimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus with rapid steroid withdrawal</intervention_name>
    <description>Basiliximab induction (4 mg i.v., days 0 and 4).
Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.
Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.
Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.</description>
    <arm_group_label>Tacrolimus with rapid steroid withdrawal</arm_group_label>
    <other_name>Simulect; Dacortin; Prograf/Advagraf; Cellcept/Myfortic.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus with steroids minimization</intervention_name>
    <description>Basiliximab induction (4 mg i.v., days 0 an 4)
Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.
Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.
Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.</description>
    <arm_group_label>Tacrolimus with steroids minimization</arm_group_label>
    <other_name>Simulect; Dacortin; Prograf/Advagraf; Cellcept/Myfortic.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA with steroid minimization</intervention_name>
    <description>Basiliximab induction (4 mg i.v., days 0 an 4)
Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.
CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.
Mycophenolate mofetil 1 gr b.i.d</description>
    <arm_group_label>CsA with steroid minimization</arm_group_label>
    <other_name>Simulect; Dacortin; Sandimmun Neoral; Cellcept/Myfortic.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary renal transplant recipients with end stage renal disease

          -  No prior history of diabetes mellitus before transplant

          -  Absence of Immunologic risk defined by the investigator criterion and Panel Reactive
             Antibody (PRA) &lt; 50%

          -  Absence of severe infection and hepatitis C or B infection

          -  Efficient contraception in women during the study

        Additionally must meet one of these &quot;Metabolic Criteria

          -  Recipient age &gt;or =60 or

          -  Recipient age between 45 and 59 years and at least one of the following metabolic
             criteria: Prior to transplantation Triglycerides (TGS) &gt;200mg/dl or the combination of
             a body mass index (BMI)&gt; 27 and Triglycerides&gt;150 mg/dl or the combination of
             HDL-cholesterol&lt;40 mg/dl for men or &lt;50 mg/dl for women and Triglycerides &gt;150 mg/dl.

        Exclusion Criteria:

          -  Patients with type I or II diabetes prior to transplantation defined by the American
             Diabetes Association (ADA) criteria

          -  Recipient age under 45

          -  Patients receiving a second renal transplant

          -  Patients with high immunological risk or PRA (panel reactive antibody level) &gt;or =50%

          -  Severe infection or hepatitis C or B infection.

          -  Dual renal transplant or double transplant with any other organ.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Torres, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fundación Canaria para la Investigación Biomédica Rafael Clavijo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonio Osuna</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Domingo Hernández</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmen Díaz Corte</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlos Gómez Alamillo</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juan Manuel Díaz</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francisco Moreso</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francisco Valdés</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armando Torres Ramírez</name>
      <address>
        <city>La Laguna</city>
        <state>S/C de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roberto Gallego</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luis Pallardo</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Porrini E, Gomez MD, Alvarez A, Cobo M, Gonzalez-Posada JM, Perez L, Hortal L, García JJ, Dolores Checa M, Morales A, Hernández D, Torres A. Glycated haemoglobin levels are related to chronic subclinical inflammation in renal transplant recipients without pre-existing or new onset diabetes. Nephrol Dial Transplant. 2007 Jul;22(7):1994-9. Epub 2007 Mar 29.</citation>
    <PMID>17395658</PMID>
  </reference>
  <reference>
    <citation>Alvarez A, Fernandez J, Porrini E, Delgado P, Pitti S, Vega MJ, González-Posada JM, Rodríguez A, Pérez L, Marrero D, Luis D, Velázquez S, Hernández D, Salido E, Torres A. Carotid atheromatosis in nondiabetic renal transplant recipients: the role of prediabetic glucose homeostasis alterations. Transplantation. 2007 Oct 15;84(7):870-5.</citation>
    <PMID>17984840</PMID>
  </reference>
  <reference>
    <citation>Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation. 2007 Sep 27;84(6):706-14.</citation>
    <PMID>17893603</PMID>
  </reference>
  <reference>
    <citation>Porrini E, Delgado P, Alvarez A, Cobo M, Pérez L, González-Posada JM, Hortal L, Gallego R, García JJ, Checa M, Morales A, Salido E, Hernández D, Torres A. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant. 2008 Apr;23(4):1436-41. Epub 2007 Nov 19.</citation>
    <PMID>18029372</PMID>
  </reference>
  <reference>
    <citation>Porrini E, Moreno JM, Osuna A, Benitez R, Lampreabe I, Diaz JM, Silva I, Domínguez R, Gonzalez-Cotorruelo J, Bayes B, Lauzurica R, Ibernon M, Moreso F, Delgado P, Torres A. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. Transplantation. 2008 Apr 27;85(8):1133-8. doi: 10.1097/TP.0b013e31816b16bd.</citation>
    <PMID>18431233</PMID>
  </reference>
  <reference>
    <citation>Bayés B, Moreso F, Benítez R, Torres A, Díaz JM, Granada ML, Lauzurica R, Pastor MC, Teixidó J. [Post-transplant diabetes mellitus depending on the pre-transplant dialysis technique]. Nefrologia. 2008;28 Suppl 6:97-102. Spanish.</citation>
    <PMID>18957019</PMID>
  </reference>
  <reference>
    <citation>Porrini E, Bayes B, Diaz JM, Ibernon M, Benitez R, Domínguez R, Moreno JM, Delgado P, Lauzurica R, Silva I, Moreso F, Lampreabe I, Arias M, Osuna A, Torres A. Hyperinsulinemia and hyperfiltration in renal transplantation. Transplantation. 2009 Jan 27;87(2):274-9. doi: 10.1097/TP.0b013e318191a7d5.</citation>
    <PMID>19155984</PMID>
  </reference>
  <reference>
    <citation>Porrini EL, Díaz JM, Moreso F, Delgado Mallén PI, Silva Torres I, Ibernon M, Bayés-Genís B, Benitez-Ruiz R, Lampreabe I, Lauzurrica R, Osorio JM, Osuna A, Domínguez-Rollán R, Ruiz JC, Jiménez-Sosa A, González-Rinne A, Marrero-Miranda D, Macía M, García J, Torres A. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2016 Mar;31(3):495-505. doi: 10.1093/ndt/gfv368. Epub 2015 Nov 3.</citation>
    <PMID>26538615</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Rodríguez AE, Triñanes J, Porrini E, Velázquez-García S, Fumero C, Vega-Prieto MJ, Díez-Fuentes ML, Luis Lima S, Salido E, Torres A. Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus. Nefrologia. 2015;35(3):264-72. doi: 10.1016/j.nefro.2015.05.007. Epub 2015 Jun 27. English, Spanish.</citation>
    <PMID>26299169</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Rodriguez AE, Triñanes J, Velazquez-Garcia S, Porrini E, Vega Prieto MJ, Diez Fuentes ML, Arevalo M, Salido Ruiz E, Torres A. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. Am J Transplant. 2013 Jul;13(7):1665-75. doi: 10.1111/ajt.12236. Epub 2013 May 7.</citation>
    <PMID>23651473</PMID>
  </reference>
  <results_reference>
    <citation>Delgado P, Diaz JM, Silva I, Osorio JM, Osuna A, Bayés B, Lauzurica R, Arellano E, Campistol JM, Dominguez R, Gómez-Alamillo C, Ibernon M, Moreso F, Benitez R, Lampreave I, Porrini E, Torres A. Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol. 2008 May;3(3):808-13. doi: 10.2215/CJN.04921107. Epub 2008 Mar 5.</citation>
    <PMID>18322043</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <results_first_submitted>February 5, 2016</results_first_submitted>
  <results_first_submitted_qc>June 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2016</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</investigator_affiliation>
    <investigator_full_name>Armando Torres Ramírez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus With Rapid Steroid Withdrawal</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus With Steroids Minimization</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="P3">
          <title>Cyclosporin A (CsA) With Steroid Minimization</title>
          <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect treatment assignment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung cancer detected before transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized. Not transplanted</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus With Rapid Steroid Withdrawal</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus With Steroids Minimization</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="B3">
          <title>CsA With Steroid Minimization</title>
          <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="7.6"/>
                    <measurement group_id="B2" value="61.6" spread="7.3"/>
                    <measurement group_id="B3" value="60.2" spread="8.3"/>
                    <measurement group_id="B4" value="61.0" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Familiar history of diabetes (N)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.95" spread="3.71"/>
                    <measurement group_id="B2" value="27.87" spread="3.72"/>
                    <measurement group_id="B3" value="27.94" spread="4.08"/>
                    <measurement group_id="B4" value="27.57" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time in dialysis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.86" spread="29.97"/>
                    <measurement group_id="B2" value="28.61" spread="23.61"/>
                    <measurement group_id="B3" value="32.95" spread="26.16"/>
                    <measurement group_id="B4" value="33.22" spread="26.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.27" spread="0.51"/>
                    <measurement group_id="B2" value="5.37" spread="0.32"/>
                    <measurement group_id="B3" value="5.31" spread="0.43"/>
                    <measurement group_id="B4" value="5.31" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.26" spread="114.93"/>
                    <measurement group_id="B2" value="199.31" spread="91.99"/>
                    <measurement group_id="B3" value="209.69" spread="109.01"/>
                    <measurement group_id="B4" value="197.60" spread="105.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.86" spread="47.99"/>
                    <measurement group_id="B2" value="162.82" spread="39.29"/>
                    <measurement group_id="B3" value="179.37" spread="42.47"/>
                    <measurement group_id="B4" value="169.40" spread="43.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-c</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.95" spread="14.37"/>
                    <measurement group_id="B2" value="42.50" spread="12.07"/>
                    <measurement group_id="B3" value="42.21" spread="15.27"/>
                    <measurement group_id="B4" value="41.85" spread="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-c</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.45" spread="36.61"/>
                    <measurement group_id="B2" value="90.00" spread="37.53"/>
                    <measurement group_id="B3" value="103.81" spread="36.03"/>
                    <measurement group_id="B4" value="97.65" spread="36.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting blood glucose level</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.91" spread="13.16"/>
                    <measurement group_id="B2" value="97.74" spread="14.29"/>
                    <measurement group_id="B3" value="91.90" spread="13.93"/>
                    <measurement group_id="B4" value="93.85" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transfusions</title>
          <units>average number of transfusions/patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.66" spread="1.27"/>
                    <measurement group_id="B2" value="0.85" spread="2.50"/>
                    <measurement group_id="B3" value="0.83" spread="2.12"/>
                    <measurement group_id="B4" value="0.78" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cold ischemia time</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.83" spread="5.52"/>
                    <measurement group_id="B2" value="18.15" spread="5.40"/>
                    <measurement group_id="B3" value="17.26" spread="6.36"/>
                    <measurement group_id="B4" value="17.41" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of the donor</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.11" spread="10.43"/>
                    <measurement group_id="B2" value="62.88" spread="8.92"/>
                    <measurement group_id="B3" value="61.62" spread="10.02"/>
                    <measurement group_id="B4" value="62.20" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor creatinine levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.80" spread="0.28"/>
                    <measurement group_id="B2" value="0.83" spread="0.40"/>
                    <measurement group_id="B3" value="0.87" spread="0.29"/>
                    <measurement group_id="B4" value="0.83" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human leucocyte antigens (HLA) class I (A, B) and class II (DR) incompatibilities</title>
          <units>number of incompatibilities</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.55" spread="1.17"/>
                    <measurement group_id="B2" value="4.00" spread="0.87"/>
                    <measurement group_id="B3" value="4.24" spread="1.10"/>
                    <measurement group_id="B4" value="3.93" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-HLA lymphocytotoxic antibodies against &lt;25% a reference panel</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome Measure &quot;New Onset Diabetes After Renal Transplantation&quot; (NODAT)</title>
        <description>American Diabetes Association criteria (ADA) including an oral glucose tolerance test.</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome Measure &quot;New Onset Diabetes After Renal Transplantation&quot; (NODAT)</title>
          <description>American Diabetes Association criteria (ADA) including an oral glucose tolerance test.</description>
          <population>Participants analyzed: participants living with a functioning graft at study end</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of patients with NODAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="21.6" upper_limit="49.5"/>
                    <measurement group_id="O2" value="23.1" lower_limit="12.7" upper_limit="38.3"/>
                    <measurement group_id="O3" value="7.9" lower_limit="2.7" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of patients without NODAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" lower_limit="50.5" upper_limit="78.4"/>
                    <measurement group_id="O2" value="76.9" lower_limit="61.6" upper_limit="87.3"/>
                    <measurement group_id="O3" value="92.1" lower_limit="79.2" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patients Treated With Insulin or Oral Antidiabetic Drugs</title>
        <time_frame>1 year</time_frame>
        <population>Participant analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Treated With Insulin or Oral Antidiabetic Drugs</title>
          <population>Participant analyzed: participants living with a functioning graft at study end.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10.5" upper_limit="34.8"/>
                    <measurement group_id="O2" value="15.4" lower_limit="7.3" upper_limit="29.7"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.5" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome Measure (Glucose Intolerance)</title>
        <description>Glycemia &gt;=140 and &lt;200 mg/dl, 2 hours after a standard oral glucose tolerance test. Measured values: glucose intolerance at 1 year defined by ADA criteria.</description>
        <time_frame>1 year</time_frame>
        <population>Participants included are those that did not develop NODAT based on not reporting the use of anti-diabetic drugs plus a fasting plasma glucose &lt;126 mg/dl .</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome Measure (Glucose Intolerance)</title>
          <description>Glycemia &gt;=140 and &lt;200 mg/dl, 2 hours after a standard oral glucose tolerance test. Measured values: glucose intolerance at 1 year defined by ADA criteria.</description>
          <population>Participants included are those that did not develop NODAT based on not reporting the use of anti-diabetic drugs plus a fasting plasma glucose &lt;126 mg/dl .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="13.7" upper_limit="46.1"/>
                    <measurement group_id="O2" value="31.0" lower_limit="17.3" upper_limit="49.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="19.2" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rejection</title>
        <description>Biopsy proven acute rejection. Measured variable: Rate of Biopsy proven acute rejection.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Rejection</title>
          <description>Biopsy proven acute rejection. Measured variable: Rate of Biopsy proven acute rejection.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="4.95" upper_limit="24.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.3" upper_limit="15.8"/>
                    <measurement group_id="O3" value="21.4" lower_limit="11.7" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function</title>
        <description>Estimated Glomerular Filtration Rate (ml/min/1.73 m^2)</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: Participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function</title>
          <description>Estimated Glomerular Filtration Rate (ml/min/1.73 m^2)</description>
          <population>Participants analyzed: Participants living with a functioning graft at study end.</population>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" lower_limit="45.2" upper_limit="58.5"/>
                    <measurement group_id="O2" value="47.4" lower_limit="42.9" upper_limit="52.0"/>
                    <measurement group_id="O3" value="44.6" lower_limit="37.8" upper_limit="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proteinuria</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Proteinuria</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" lower_limit="121" upper_limit="296"/>
                    <measurement group_id="O2" value="241" lower_limit="110" upper_limit="373"/>
                    <measurement group_id="O3" value="343.2" lower_limit="154" upper_limit="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Systolic pressure (mmHg)</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Systolic pressure (mmHg)</description>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.36" spread="15.75"/>
                    <measurement group_id="O2" value="133.97" spread="13.67"/>
                    <measurement group_id="O3" value="136.28" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Diastolic pressure (mmHg)</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Diastolic pressure (mmHg)</description>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.67" spread="8.93"/>
                    <measurement group_id="O2" value="74.59" spread="9.83"/>
                    <measurement group_id="O3" value="76.64" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Antihypertensive Drugs Patients Reported Taking.</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Antihypertensive Drugs Patients Reported Taking.</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>number of antihypertensive drugs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipidic Profile (Triglycerides)</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Lipidic Profile (Triglycerides)</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.44" spread="93.68"/>
                    <measurement group_id="O2" value="145.59" spread="52.97"/>
                    <measurement group_id="O3" value="160.78" spread="84.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipidic Profile (Cholesterol)</title>
        <description>Lipidic Profile (total cholesterol)</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Lipidic Profile (Cholesterol)</title>
          <description>Lipidic Profile (total cholesterol)</description>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.05" spread="30.57"/>
                    <measurement group_id="O2" value="178.24" spread="33.64"/>
                    <measurement group_id="O3" value="168.89" spread="33.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipidic Profile (HDL-c)</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Lipidic Profile (HDL-c)</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.84" spread="13.89"/>
                    <measurement group_id="O2" value="49.29" spread="16.90"/>
                    <measurement group_id="O3" value="48.35" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipidic Profile (LDL-c)</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Lipidic Profile (LDL-c)</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.00" spread="27.04"/>
                    <measurement group_id="O2" value="95.43" spread="26.54"/>
                    <measurement group_id="O3" value="88.65" spread="25.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Using Statins</title>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Using Statins</title>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56." lower_limit="41" upper_limit="70"/>
                    <measurement group_id="O2" value="61.5" lower_limit="45.9" upper_limit="75.1"/>
                    <measurement group_id="O3" value="73.7" lower_limit="58" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Carotid Intima-media Thickness Over Time</title>
        <description>absolute difference between carotid intima-media thickness at study end versus baseline.</description>
        <time_frame>1 year</time_frame>
        <population>Participants analyzed: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Carotid Intima-media Thickness Over Time</title>
          <description>absolute difference between carotid intima-media thickness at study end versus baseline.</description>
          <population>Participants analyzed: participants living with a functioning graft at study end.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.09" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.15" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.01" lower_limit="-0.01" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Using Acetylsalicylic Acid (ASA)</title>
        <time_frame>1 year</time_frame>
        <population>Analysis population description: participants living with a functioning graft at study end.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus With Rapid Steroid Withdrawal</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus With Steroids Minimization</title>
            <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
          <group group_id="O3">
            <title>CsA With Steroid Minimization</title>
            <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Using Acetylsalicylic Acid (ASA)</title>
          <population>Analysis population description: participants living with a functioning graft at study end.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" lower_limit="38.6" upper_limit="68.4"/>
                    <measurement group_id="O2" value="48.7" lower_limit="33.5" upper_limit="64.1"/>
                    <measurement group_id="O3" value="52.8" lower_limit="37" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus With Rapid Steroid Withdrawal</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
Tacrolimus with rapid steroid withdrawal: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus With Steroids Minimization</title>
          <description>Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
Tacrolimus with steroids minimization: Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month, and MMF 2 gr/day; steroids: 0.5 gr of MP intraoperatively and 60 mg day 1; followed by oral doses of prednisone and gradual tapering to complete discontinuation over 6 months. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
        <group group_id="E3">
          <title>CsA With Steroid Minimization</title>
          <description>CsA plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
CsA with steroid minimization: CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month, and similar pattern with MMF and steroids as group 2. Basiliximab induction (4 mg, days 0 and 4).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart attack resulting in death event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Shock resulting in death event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Rejection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Graft Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia resulting in death event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sepsis resulting in death event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Miocardial Infarction or Coronary Revascularization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK Virus Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CMV Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Acute Pyelonephritis of the graft</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Armando Torres Ramírez</name_or_title>
      <organization>Hospital Universitario de Canarias. Universidad de La Laguna. Spain</organization>
      <phone>+34630989515</phone>
      <email>atorres@ull.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

